{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:28:11Z","timestamp":1790663291036,"version":"4.1.0"},"reference-count":64,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,12,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In 2017, 4 drugs received US Food and Drug Administration marketing approval for acute myeloid leukemia (AML) treatment: targeted therapies for mutant FLT3 and IDH2, a liposomal cytarabine-daunorubicin formulation for therapy-related AML and AML with myelodysplasia-related changes, and resurgence of an antibody-drug conjugate designed to target CD33. Promising results also emerged for the BCL-2 inhibitor venetoclax combined with low-intensity therapy in older patients unfit for intensive chemotherapy. This quintet of new drugs is likely to reshape the therapeutic landscape of AML.<\/jats:p>","DOI":"10.1182\/blood-2017-08-784066","type":"journal-article","created":{"date-parts":[[2017,10,19]],"date-time":"2017-10-19T13:55:23Z","timestamp":1508421323000},"page":"2469-2474","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":114,"title":["Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML"],"prefix":"10.1182","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7514-3298","authenticated-orcid":false,"given":"Andrew H.","family":"Wei","sequence":"first","affiliation":[{"name":"Department of Clinical Haematology, Alfred Hospital, Melbourne, Australia; Australian Centre for Blood Diseases, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7417-4343","authenticated-orcid":false,"given":"Ing S.","family":"Tiong","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, Alfred Hospital, Melbourne, Australia; Australian Centre for Blood Diseases, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"33","key":"2019111903311367300_B1","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1200\/JCO.2012.44.2962","article-title":"Boulevard of broken dreams: drug approval for older adults with acute myeloid leukemia","volume":"30","author":"Sekeres","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2-3","key":"2019111903311367300_B2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0163-7258(99)00005-4","article-title":"Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent","volume":"82","author":"Fabbro","year":"1999","journal-title":"Pharmacol Ther"},{"issue":"5","key":"2019111903311367300_B3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S1535-6108(02)00069-7","article-title":"Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412","volume":"1","author":"Weisberg","year":"2002","journal-title":"Cancer Cell"},{"issue":"5","key":"2019111903311367300_B4","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"2019111903311367300_B5","author":"Levis","year":"2013"},{"issue":"23","key":"2019111903311367300_B6","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111903311367300_B7","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2016-01-693879","article-title":"Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia","volume":"128","author":"Metzeler","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2019111903311367300_B8","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1182\/blood-2007-08-109090","article-title":"The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia","volume":"111","author":"Gale","year":"2008","journal-title":"Blood"},{"issue":"9","key":"2019111903311367300_B9","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1182\/blood-2016-07-730648","article-title":"A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML","volume":"129","author":"Knapper","year":"2017","journal-title":"Blood"},{"issue":"16","key":"2019111903311367300_B10","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S1470-2045(15)00362-9","article-title":"Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial","volume":"16","author":"R\u00f6llig","year":"2015","journal-title":"Lancet Oncol"},{"issue":"11","key":"2019111903311367300_B11","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Mardis","year":"2009","journal-title":"N Engl J Med"},{"issue":"22","key":"2019111903311367300_B12","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N Engl J Med"},{"issue":"22","key":"2019111903311367300_B13","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2019111903311367300_B14","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/leu.2016.275","article-title":"Isocitrate dehydrogenase mutations in myeloid malignancies","volume":"31","author":"Medeiros","year":"2017","journal-title":"Leukemia"},{"issue":"7274","key":"2019111903311367300_B15","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"issue":"2","key":"2019111903311367300_B16","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1084\/jem.20092506","article-title":"Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations","volume":"207","author":"Gross","year":"2010","journal-title":"J Exp Med"},{"issue":"3","key":"2019111903311367300_B17","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"issue":"6","key":"2019111903311367300_B18","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2019111903311367300_B19","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1182\/blood-2017-04-779447","article-title":"Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response","volume":"130","author":"Amatangelo","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2019111903311367300_B20","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/leu.2017.46","article-title":"Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo","volume":"31","author":"Chaturvedi","year":"2017","journal-title":"Leukemia"},{"issue":"23","key":"2019111903311367300_B21","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1182\/blood.V126.23.1306.1306","article-title":"Molecular profiling and relationship with clinical response in patients with IDH1 mutation-positive hematologic malignancies receiving AG-120, a first-in-class potent inhibitor of mutant IDH1, in addition to data from the completed dose escalation portion of the phase 1 study","volume":"126","author":"DiNardo","year":"2015","journal-title":"Blood"},{"issue":"18","key":"2019111903311367300_B22","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1200\/JCO.2013.52.8562","article-title":"International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed\/refractory acute myeloid leukemia","volume":"32","author":"Roboz","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111903311367300_B23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2019111903311367300_B24","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/leu.2016.71","article-title":"Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate","volume":"30","author":"Chaturvedi","year":"2016","journal-title":"Leukemia"},{"issue":"8","key":"2019111903311367300_B25","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.clml.2016.04.006","article-title":"Evidence for clinical differentiation and differentiation syndrome in patients with acute myeloid leukemia and IDH1 mutations treated with the targeted mutant IDH1 inhibitor, AG-120","volume":"16","author":"Birendra","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"2019111903311367300_B26","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1158\/1535-7163.MCT-06-0118","article-title":"Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice","volume":"5","author":"Mayer","year":"2006","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"2019111903311367300_B27","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.exphem.2011.04.001","article-title":"Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells","volume":"39","author":"Kim","year":"2011","journal-title":"Exp Hematol"},{"issue":"8","key":"2019111903311367300_B28","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.3109\/10428194.2010.490312","article-title":"Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts","volume":"51","author":"Lim","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2019111903311367300_B29","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1200\/JCO.2010.30.5961","article-title":"First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia","volume":"29","author":"Feldman","year":"2011","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111903311367300_B30","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1182\/blood-2013-12-540971","article-title":"Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine\/daunorubicin, vs cytarabine\/daunorubicin in older adults with untreated AML","volume":"123","author":"Lancet","year":"2014","journal-title":"Blood"},{"key":"2019111903311367300_B31","author":"Lancet","year":"2016"},{"issue":"7","key":"2019111903311367300_B32","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/modpathol.2015.55","article-title":"Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia","volume":"28","author":"Weinberg","year":"2015","journal-title":"Mod Pathol"},{"issue":"20","key":"2019111903311367300_B33","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"2019111903311367300_B34","author":"Swerdlow","year":"2008"},{"issue":"2","key":"2019111903311367300_B35","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/cncr.28974","article-title":"Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML","volume":"121","author":"Cortes","year":"2015","journal-title":"Cancer"},{"issue":"6","key":"2019111903311367300_B36","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2019111903311367300_B37","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1038\/sj.leu.2402677","article-title":"Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)","volume":"16","author":"Larson","year":"2002","journal-title":"Leukemia"},{"issue":"24","key":"2019111903311367300_B38","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"issue":"21","key":"2019111903311367300_B39","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1182\/blood.V118.21.79.79","article-title":"Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR Study","volume":"118","author":"Delaunay","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2019111903311367300_B40","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial","volume":"29","author":"Burnett","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9825","key":"2019111903311367300_B41","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"issue":"32","key":"2019111903311367300_B42","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2012.42.2964","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia","volume":"30","author":"Burnett","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111903311367300_B43","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol"},{"issue":"6","key":"2019111903311367300_B44","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3324\/haematol.2016.141937","article-title":"Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg\/m2 with 6 mg\/m2 in the NCRI AML17 Trial","volume":"101","author":"Burnett","year":"2016","journal-title":"Haematologica"},{"issue":"1","key":"2019111903311367300_B45","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/sj.leu.2404434","article-title":"High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group","volume":"21","author":"Taksin","year":"2007","journal-title":"Leukemia"},{"key":"2019111903311367300_B46","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.leukres.2016.03.004","article-title":"Evaluation of gemtuzumab ozogamycin associated sinusoidal obstructive syndrome: Findings from an academic pharmacovigilance program review and a pharmaceutical sponsored registry","volume":"44","author":"Magwood-Golston","year":"2016","journal-title":"Leuk Res"},{"issue":"10","key":"2019111903311367300_B47","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1182\/blood.V97.10.3197","article-title":"Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells","volume":"97","author":"van Der Velden","year":"2001","journal-title":"Blood"},{"key":"2019111903311367300_B48","unstructured":"FDA Oncologic Drugs Advisory Committee Briefing Document - Mylotarg. (gemtuzumab ozogamicin). July 11, 2017. https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/OncologicDrugsAdvisoryCommittee\/UCM566013.pdf. Accessed 8 October 2017."},{"issue":"22","key":"2019111903311367300_B49","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood.V128.22.896.896","article-title":"ATRA, arsenic trioxide (ATO), and gemtuzumab ozogamicin (GO) is safe and highly effective in patients with previously untreated high-risk acute promyelocytic leukemia (APL): final results of the SWOG\/Alliance\/ECOG S0535 Trial","volume":"128","author":"Lancet","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2019111903311367300_B50","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2016-09-736686","article-title":"Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab","volume":"129","author":"Abaza","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2019111903311367300_B51","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.3324\/haematol.2011.043786","article-title":"High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation","volume":"96","author":"De Propris","year":"2011","journal-title":"Haematologica"},{"issue":"22","key":"2019111903311367300_B52","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1182\/blood.V128.22.1709.1709","article-title":"Correlative biomarkers of response to venetoclax in combination with chemotherapy or hypomethylating agents in elderly untreated patients with acute myeloid leukemia","volume":"128","author":"Chyla","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2019111903311367300_B53","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00277-015-2351-x","article-title":"Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States","volume":"94","author":"Medeiros","year":"2015","journal-title":"Ann Hematol"},{"issue":"7","key":"2019111903311367300_B54","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/leu.2016.65","article-title":"Genetic alterations and their clinical implications in older patients with acute myeloid leukemia","volume":"30","author":"Tsai","year":"2016","journal-title":"Leukemia"},{"issue":"24","key":"2019111903311367300_B55","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1002\/cncr.30220","article-title":"Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups","volume":"122","author":"Creutzig","year":"2016","journal-title":"Cancer"},{"issue":"21","key":"2019111903311367300_B56","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111903311367300_B57","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/cncr.22496","article-title":"A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment","volume":"109","author":"Burnett","year":"2007","journal-title":"Cancer"},{"issue":"6","key":"2019111903311367300_B58","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1182\/blood-2002-06-1714","article-title":"Amount of spontaneous apoptosis detected by Bax\/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML)","volume":"101","author":"Del Poeta","year":"2003","journal-title":"Blood"},{"issue":"10","key":"2019111903311367300_B59","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"issue":"s2","key":"2019111903311367300_B60","first-page":"S472","article-title":"Safety and efficacy of venetoclax (Ven) in combination with decitabine or azacitidine in treatment-naive, elderly patients (\u226565 years) with acute myeloid leukemia (AML)","volume":"102","author":"Pratz","year":"2017","journal-title":"Haematologica"},{"issue":"s2","key":"2019111903311367300_B61","first-page":"S473","article-title":"Venetoclax plus low-dose cytarabine in treatment-naive acute myeloid leukemia patients aged \u226565 years and unfit for standard induction therapy","volume":"102","author":"Wei","year":"2017","journal-title":"Haematologica"},{"issue":"13","key":"2019111903311367300_B62","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","article-title":"High-dose daunorubicin in older patients with acute myeloid leukemia [published correction appears in N Engl J Med. 2010;362(12):1155]","volume":"361","author":"L\u00f6wenberg","year":"2009","journal-title":"N Engl J Med"},{"issue":"7626","key":"2019111903311367300_B63","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"issue":"s2","key":"2019111903311367300_B64","first-page":"175","article-title":"A dual BH3-mimetic approach targeting both BCL-2 and MCL1 is highly efficacious and well-tolerated in acute myeloid leukemia","volume":"102","author":"Moujalled","year":"2017","journal-title":"Haematologica"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/23\/2469\/1403905\/blood784066.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/23\/2469\/1403905\/blood784066.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T03:31:38Z","timestamp":1574134298000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/130\/23\/2469\/36739\/Midostaurin-enasidenib-CPX351-gemtuzumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,7]]},"references-count":64,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2017,12,7]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-08-784066","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,7]]}}}